Menu
← Oncology Approval Tracker
FDA DECISION ·
Lunsumio Velo
mosunetuzumab-axgb · Genentech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Subcutaneous treatment of adults with relapsed or refractory follicular lymphoma after two or more systemic treatment lines.
LAMPGEN ANALYSIS
Why it matters
The new route gives this CD20×CD3 bispecific an additional administration option under accelerated approval.
What research teams should watch
Separate Lunsumio Velo and IV Lunsumio order sets and train teams on route-specific step-up dosing and cytokine release syndrome management.
PRIMARY RECORDS